ASHM Report Back
Clinical posts from members and guests of the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) from various international medical and scientific conferences on HIV, AIDS, viral hepatitis, and sexual health.
HepatitisC In Primary Care and Drug and Alcohol Settings (Sunday 5th Novemeber 2017)
The injecting drug population in Australia contribute to 90% of newly diagnosed HepC, making health professionals working in the Drug and Alcohol sector pivotal to the health care outcomes of this community. From a public health perspective better healthcare post diagnosis would reduce the the advanced progress of the disease by encouraging early thus reducing commodities.
We now have effective treatments that cure.
A discussion on what it is like to live with HepC and the past experiences with older injectable treatment V's new oral treatments, with highly successful cure rates was most insightful into the progression of the treatment journey for individuals diagnosed. Those individuals diagnosed who had experienced the older treatments with severe side effects and no success of clearing the virus, moved to using the new treatments with next to no side effects and had clearance of the infection within 12 weeks.
In 2016 reported cases of of HepC in Australia was 230,000. High risks groups need a holistic approach to care taking into account behavioral and social aspects. However recommendations are to treat first and deal with other lifestyle and behavioral issues later. This way we keep the client engaged in services
A great resource for health practitioners www.gesa.org.au (HepC treatments and Genotypes)
Interactive polling was used during this presentation to determine the group knowledge of testing and treatments for HepC.